eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

SCImago Journal & Country Rank
 
2/2006
vol. 5
 
Share:
Share:
more
 
 
abstract:

Platelet hemostasis and endothelial status in postmenopausal women with some risk factors for coronary heart disease – the impact of hormonal therapy and anti-thrombotic prophylaxis

Grzegorz Stachowiak
,
Jolanta Niewiarowska
,
Magdalena Wiktorska
,
Izabela Papiewska-Pająk
,
Izabela Sacewicz
,
Tomasz Pertyński

Prz Menopauz 2006; 2: 102–108
Online publish date: 2006/05/12
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 

Aim of study:
the influence of transdermal hormone therapy (tHT) and anti-thrombotic prophylaxis (low doses of acetylsalicylic acid – ASA) on platelet hemostasis and endothelial function of menopausal women with risk factors for coronary heart disease (CHD).
Material and methods:
Study group were menopausal women (with 2 or more CHD risk factors) in which tHT composed of 17β-estradiol and NETA (G1, n=22) or the above tHT combined with low ASA doses were administered (ASA) (n=23). Controls were 16 premenopausal women. The following parameters were measured in blood: GP IIb/IIIa, E-selectin, endothelin-1 (ET-1), u-PAR. Duration of the therapy was 3 months.
Results:
Three-month treatment, both as tHT in G1, as well as tHT+ASA in G2, had no significant influence on the levels of GP IIb/IIIa, E-selectin, ET-1 and u-PAR. At the beginning of the study (T0), both groups of postmenopausal women were characterized, as compared to the premenopausal controls, by the higher levels of platelet receptor – GP IIb/IIIa.
Conclusions:
1. Three-month tHT applied in the group of menopausal women with CHD risk factors did not influence endothelial function and platelet hemostasis. 2. The use of low ASA doses, as the anti-thrombotic prophylaxis of tHT in postmenopausal women with CHD risk factors, is not indicated. 3. Disadvantageous alterations in platelet hemostasis are observed after menopause.
keywords:

menopause, endothelium, platelets, hormone therapy, acetylsalicylic acid, coronary heart disease

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.